Cryo-Cell International, Inc Stock News

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announ

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992,

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announc

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, anno

CRYO-CELL International press release (CCEL): FY GAAP EPS of $0.00.Revenue of $28.9M (-7.1% Y/Y).

Cryo-Cell International has a stable business that generates consistent cash flow. The company is close to monetizing a partnership with Duke University to bring patented stem cell treatments to marke

The global stem cell banking market size is expected to reach USD 15.58 Billion in 2028 and register a CAGR of 9.3% over the forecast period. The "Stem Cell Banking Market" report 2021 includes business aspects such as the predominant trends

Cryo-Cell International (OTCMKTS: CCEL) is one of 31 publicly-traded companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it compare to its rivals? We will compare Cryo-Cell International to related companies based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, risk and analyst recommendations. Valuation & []

Cryo-Cell International (OTCMKTS: CCEL) is one of 31 publicly-traded companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it weigh in compared to its rivals? We will compare Cryo-Cell International to similar businesses based on the strength of its valuation, earnings, institutional ownership, dividends, risk, profitability and analyst recommendations. []

Cryo-Cell International (OTCMKTS: CCEL) is one of 31 publicly-traded companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it compare to its rivals? We will compare Cryo-Cell International to similar companies based on the strength of its risk, dividends, analyst recommendations, earnings, profitability, institutional ownership and valuation. Institutional & []

Cryo-Cell International (OTCMKTS: CCEL) is one of 31 publicly-traded companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it contrast to its competitors? We will compare Cryo-Cell International to related companies based on the strength of its analyst recommendations, valuation, earnings, dividends, profitability, institutional ownership and risk. Analyst Recommendations []

Cryo-Cell International (OTCMKTS: CCEL) is one of 31 public companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it weigh in compared to its competitors? We will compare Cryo-Cell International to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation. []

Cryo-Cell International (OTCMKTS: CCEL) is one of 30 publicly-traded companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it contrast to its peers? We will compare Cryo-Cell International to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, earnings, dividends and profitability. Analyst Ratings []

Cryo-Cell International (OTCMKTS: CCEL) is one of 30 public companies in the Miscellaneous health & allied services, not elsewhere classified industry, but how does it contrast to its rivals? We will compare Cryo-Cell International to related companies based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability. Volatility & []